Abstract
2085 Background: Evidence impl icating cyclooxygenase-2 (Cox-2) in tumor angiogenesis has prompted evaluation of Cox-2 inhibitors in cancer treatment. Hepatic metabolism by cytochrome P450 2C9 (CYP2C9) is a major route of elimination for celecoxib. Several commonly used antiepileptics induce CYP2C9. This study was conducted to determine the effects of enzyme inducing antiepileptic drugs (EIAEDs) on the pharmacokinetics of celecoxib. Secondary objectives were to determine the safety of celecoxib in this setting and estimate survival when celecoxib was administered concurrently with radiation therapy in pts with newly diagnosed glioblastoma multiforme. Methods: Pts were divided into +EIAED and −EIAED groups. Celecoxib was begun one week before radiation. A 400 mg dose was taken on day 1 followed by 400 mg bid until tumor progression, dose limiting toxicity, or study withdrawal. No adjuvant chemotherapy was permitted. Pharmacokinetic samples were obtained from day 1 to week 6 and assayed using a validated LC...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
